PENTERO 900: Elevating Excellence in Microsurgery to a New Level

DUBLIN, Calif., April 14, 2011 /PRNewswire/ -- Carl Zeiss Meditec, Inc., introduced the all-new PENTERO® 900 surgical microscope system at the 79th Annual Meeting of the American Association of Neurological Surgeons (AANS) in Denver, Colo. Based on the breakthrough OPMI® Pentero surgical visualization platform launched in 2004, PENTERO 900 offers innovative new features and customer benefits such as:

HD quality for education, presentations and patient documentation

PENTERO 900 offers razor-sharp images in HD quality – camera, recorder, editor and touchscreen monitor are all contained in a fully integrated HD chain. The playback of high resolution HD images and videos is beneficial for surgeons during live demonstrations, resident education, presentations and patient documentation.

New fields of application for fluorescence

The YELLOW 560 option visualizes fluorescence in the wavelength range from 540 to 690nm supporting new fields of application and research. YELLOW 560 effectively complements the existing ZEISS fluorescence portfolio including BLUE 400, INFRARED 800 and FLOW 800 modules, paving the way for future application developments.

Comfortable working positions with new foldable binocular tube

The Foldable Tube f170/f260 combines brilliant apochromatic optics and a revolutionary design for maximum visualization flexibility, magnification potential and positioning ergonomics. It offers surgeons an unprecedented range of comfortable working positions, even at extreme surgical approach angles. The PROMAG™ function instantly yields a 50 percent gain in magnification for delicate and detailed procedures.

"When we introduced OPMI Pentero to the market in 2004, we set new, pioneering standards in the user-oriented enhancement of surgical microscope design. With the new features on PENTERO 900, we are propelling the microsurgical platform into a new dimension," said Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology suppliers. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. In the 2009/2010 (30 September) financial year, around 2,200 employees generated revenue of EUR 676 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. In financial year 2009/2010, the Group generated revenue of around EUR 2.98 billion. From financial year 2010/2011 onwards, eyeglass lens manufacturer Carl Zeiss Vision shall be integrated as an autonomous business group (revenue of around EUR 880 million in financial year 2009/2010). The Carl Zeiss Group thus employs a workforce of around 24,000 worldwide, more than 10,000 of whom are based in Germany. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For further information see: http://www.meditec.zeiss.com

Contact:

SOURCE Carl Zeiss Meditec, Inc.